KalVista Pharmaceuticals reports incentive grants pursuant to Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the Compensation Committee of KalVista’s Board of Directors has granted nine newly hired employees incentive options to purchase an aggregate of 55,000 shares of KalVista common stock on September 3, 2024, as an incentive for each employee entering into employment with KalVista. The options were granted pursuant to Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $12.37 per share, which is equal to the closing price of KalVista’s common stock on the date of grant. One-quarter of the options will vest on the first anniversary of the grant commencement date, with the remainder vesting in equal monthly installments over the next three years, in each case subject to the new employee’s continued employment with the Company. Each stock option will have a term of 10 years and will be subject to the terms of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.